Mark Dawson: A Radical Rethink of Hemophilia Treatment
Mark Dawson, Head of Roche Pharma Research and Early Development (pRED) at Roche, shared a post on LinkedIn:
“As a hematologist, few moments in medical history stand out as profoundly as the evolution of hemophilia care.
For decades, our reliance on donor-derived blood products led to tragedy – patients I personally cared for survived their bleeding disorders only to face the consequences of receiving contaminated transfusions carrying HIV and Hepatitis C.
Recombinant factor therapies finally brought safety, but the relentless burden of frequent infusions and the development of factor VIII inhibitors remained.
The true inflection point wasn’t an incremental improvement; it was a radical rethink.
By engineering a bispecific antibody to mimic the cofactor function of coagulation factor VIII, researchers bypassed factor replacement entirely and redefined the therapeutic paradigm.
I am delighted to see three visionary scientists, including our esteemed colleagues at Chugai, honored with the Lasker Award for this breakthrough.
It is a well-deserved recognition of that extraordinary leap in medicine.
Huge congratulations to the winners for their deep curiosity, sharp scientific thinking, and for fundamentally altering the natural history of this disease.
Your achievement is a masterclass in what happens when we challenge conventional thinking to transform human health.”
Stay updated with Hemostasis Today.
-
Sep 10, 2026, 16:53Flora Peyvandi: A New Approach to Coagulation with Bispecific Antibodies
-
Sep 10, 2026, 16:52Francisco Chacón-Lozsán: Perhaps We Are Treating ‘Sepsis’ When We Should Be Treating an Immune Phenotype
-
Sep 10, 2026, 16:46Aswin K Mohan: HLA Beyond Histocompatibility – Redefining Immune Recognition in Modern Medicine
-
Sep 10, 2026, 16:40Satyam Arora: Pediatric Apheresis – When Every Millilitre Matters
-
Sep 10, 2026, 16:39Marco Moscarelli: When CT Reveals Thrombosis After TAVI
-
Sep 10, 2026, 16:23Antonio Paul: When a Low Platelet Count Does Not Mean Weak Clotting
-
Sep 10, 2026, 16:12Balancing Thrombosis and Bleeding in Antiphospholipid Syndrome
-
Sep 10, 2026, 16:07Miguel Teran: Why ROTEM Will Redefine Major Bleeding Management
-
Sep 10, 2026, 16:04Isaac Okello: Where Skyline Meets Savannah – Quiet Moments at GASCDO in Nairobi